Quantum Leap Healthcare Collaborative

News & Announcements

Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.
I-SPY Email List Sign-up

I-SPY News

I-SPY founder Dr. Laura Esserman Honored: OncLive® To Induct the 2018 Class of Giants of Cancer Care®

OncLive® announced Dr. Laura Esserman as an inductee of the 2018 Giants of Cancer Care® recognition program.

News Update

May 26, 2018

Long-term efficacy results from the I-SPY 2 TRIAL indicate pathological complete response (pCR) is a powerful predictor for breast cancer survival

Data Presented at San Antonio Breast Cancer Symposium Show Significant and Clinically Impactful Relationship Between pCR and Event-Free Survival in High-Risk Breast Cancer.

Press Release

December 7, 2017

I-SPY 2 TRIAL predictive biomarker analysis shows promise to improve targeted therapy for high-risk breast cancers

New Data Analyses Presented at San Antonio Breast Cancer Symposium Spotlight Predictive Response to Pembrolizumab and MK-2206, and Demonstrate Improved Predictive Performance of Breast MRI

Press Release

December 7, 2017

Natera's Personalized CtDNA Technology Now Part Of I-SPY 2 TRIAL

With this new technology, the I-SPY 2 TRIAL can better help match agents, combinations, and additional targeted interventions to women with high-risk breast cancers.

Press Release

August 21, 2017

New Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes with Combination of Merck’s KEYTRUDA® (pembrolizumab) Plus Standard Neoadjuvant Therapy in Patients with High-Risk Breast Cancer

Data to Be Presented at 2017 ASCO Annual Meeting Include Findings in Patients with Locally Advanced Triple-Negative (TNBC) and Hormone Receptor-Positive/HER2-Negative (HR+/HER2-) Breast Cancers

Press Release

June 5, 2017

Healio Mentions I-SPY 2 Trial In "Five Updates For Triple Negative Breast Cancer Day"

In conjunction with Triple Negative Breast Cancer Day, HemOnc Today presents five updates in the treatment of triple-negative breast cancer and on associated disparities that may impact your practice.

News Update

March 3, 2017

Oncology Nursing News Mentions I-SPY Trials In New Agents, Combinations Showing Durable Benefit In Triple-Negative Breast Cancer

The triple-negative breast cancer (TNBC) pipeline is transforming, experts say, with the potential additions of immunotherapy and PARP inhibitors.

News Update

February 24, 2017

Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer

A new treatment arm of the I-SPY2 TRIAL will include patritumab, an investigational anti-HER3 monoclonal antibody

Press Release

October 25, 2016

New England Journal of Medicine Underscores Success of the I-SPY 2 Clinical Trial Model as Promising Results are Published for Two Breast Cancer Drugs Investigated in the Study

Two articles published today in the July 7, 2016 issue of the New England Journal of Medicine highlight the innovative nature and utility of I-SPY2

Press Release

July 7, 2016

T-DM1 (Kadcyla) and pertuzumab (Perjeta) Show Promise for Women with HER2-positive Breast Cancer

Pre-surgery Combination Therapy Lessens Short and Long-term Toxicity and Could Mean Development of Fewer Recurrent Metastatic Breast Cancers

Press Release

April 18, 2016

Keytruda, talazoparib join I-SPY 2

QuantumLeap Healthcare Collaborative Announces Inclusion of MERCK’s KEYTRUDA (pembrolizumab) and MEDIVATION’s Talazoparib PARP-Inhibitor for I-SPY 2 TRIAL in Breast Cancer

Press Release

March 21, 2016

Merck & Co. MK-2206 "Graduates" From I-SPY 2

MK-2206 plus standard neoadjuvant therapy beneficial in all hormone receptor (HR)-negative, all HER2-positive, and HR-negative/HER2-positive tumors

Press Release

June 1, 2015